Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Overview of attention for article published in Arthritis Research & Therapy, January 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

So far, Altmetric has seen 14 X posts from 13 X users, with an upper bound of 35,730 followers.

RT @GRESSER_Espa: Ixekizumab en #ArPs a largo plazo. Os dejo el artículo en abierto! 🔑🔑🔑 @SEReumatologia @LillyES https://t.co/YC1jic6kn…

RT @NatRevRheumatol: #ResearchHighlight | Long-term safety of ixekizumab confirmed in #PsoriaticArthritis Read the original research from…

RT @NatRevRheumatol: #ResearchHighlight | Long-term safety of ixekizumab confirmed in #PsoriaticArthritis Read the original research from…

RT @GRESSER_Espa: Ixekizumab en #ArPs a largo plazo. Os dejo el artículo en abierto! 🔑🔑🔑 @SEReumatologia @LillyES https://t.co/YC1jic6kn…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.